PubMed Health⌕ Search

PubMed · 17061895

Solvent effects in thermodynamically controlled multicomponent nanocage syntheses.

Abstract

The solvent effects on the condensation reaction between tetraformylcavitand 2 and ethylene-1,2-diamine 3 are reported. Earlier, it was found that the trifluoroacetic acid-catalyzed condensation of 2 and 2 equiv of 3 in CHCl(3) provides in 82% yield an octahedral nanocage 1 composed of 6 cavitands that are linked together by 12 -CH=N-CH(2)CH(2)-N=CH- linker groups (Liu, X.; Liu, Y.; Li, G.; Warmuth, R. Angew. Chem., Int. Ed. 2006, 45, 901). In tetrahydrofuran, the same reactants yield a tetrameric nanocage 4 (35% yield), which resembles a distorted tetrahedron built up from four cavitands that occupy the apexes. Each cavitand is doubly linked to one other cavitand and singly linked to the other two cavitands via -CH=N-CH(2)CH(2)N=CH- connectors. In CH(2)Cl(2), the reaction between 8 2 and 16 3 yields a square antiprismatic nanocage 5 (65% yield), in which each cavitand occupies one of the eight corners and is connected to four neighboring cavitands via -CH=N-CH(2)CH(2)-N=CH- linkers. Nanocage 5 is also the main product in CH(2)ClCH(2)Cl (26% yield) and CHCl(2)CHCl(2) (33% yield). Reduction of all imine bonds in 4 and 5 yields polyaminonanocontainers 7 and 8, respectively, which were isolated as trifluoroacetate salts. Contrary to the formation of larger capsules composed of four, six, or eight cavitands in the reaction between 2 and 3, the acid-catalyzed reaction of 2 with 2 equiv of H(2)N-X-NH(2) (X = (CH(2))(n)(=3,4,5), 1,3-C(6)H(4), 1,4-(CH(2))(2)C(6)H(4), or 1,3-(CH(2))(2)C(6)H(4)) quantitatively yields octaiminohemicarcerands 9-14, in which two cavitands are connected with four -CH=N-X-N=CH- linkers. The outcomes of these condensation reactions are rationalized with the different diamine structures and the relative orientation of cavitands in 1, 4, 5, and 9-14.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Xuejun Liu, Ralf Warmuth. 2006-11-01. Solvent effects in thermodynamically controlled multicomponent nanocage syntheses.. https://doi.org/10.1021/ja0644733

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗